Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 342

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy

Open access
Héritier, Sébastien, Emile, Jean-François, Barkaoui, Mohamed-Aziz, Thomas, Caroline, Fraitag, Sylvie, Boudjemaa, Sabah, Renaud, Florence, Moreau, Anne, Peuchmaur, Michel, Chassagne-Clément, Catherine, Dijoud, Frédérique, Rigau, Valérie, Moshous, Despina, Lambilliotte, Anne, Mazingue, Françoise, Kebaili, Kamila, Miron, Jean, Jeziorski, Eric, Plat, Geneviève, Aladjidi, Nathalie, Ferster, Alina, Pacquement, Hélène, Galambrun, Claire, Brugières, Laurence, Leverger, Guy, Mansuy, Ludovic, Paillard, Catherine, Deville, Anne, Armari-Alla, Corinne, Lutun, Anne, Gillibert-Yvert, Marion, Stephan, Jean-Louis, Cohen-Aubart, Fleur, Haroche, Julien, Pellier, Isabelle, Millot, Frédéric, Lescoeur, Brigitte, Gandemer, Virginie, Bodemer, Christine, Lacave, Roger, Hélias-Rodzewicz, Zofia, Taly, Valérie, Geissmann, Frédéric, Donadieu, Jean·2016·Journal of Clinical Oncology

Abstract

Purpose: Langerhans cell histiocytosis (LCH) is an inflammatory myeloid neoplasia with a broad spectrum of clinical manifestations and outcomes in children. The somatic BRAF V600E mutation occurs frequently, but clinical significance remains to be determined. Patients and Methods: BRAF V600E mutation was investigated in a French LCH cohort. We analyzed associations between mutation status and clinical presentation, extent of disease, reactivation rate, response to therapy, and long-term permanent sequelae. Results: Among 315 patients with successfully determined BRAF status, 173 (54.6%) carried a BRAF V600E mutation. Patients with BRAF V600E manifested more severe disease than did those with wild-type BRAF. Patients with BRAF V600E comprised 87.8% of patients (43 of 49) with multisystem LCH with risk organ involvement (liver, spleen, hematology), 68.6% of patients (35 of 51) with multisystem LCH without risk organ involvement, 43.9% of patients (86 of 196) with single-system LCH, and 42.1% of patients (8 of 19) with lung-involved LCH (P < .001). BRAF V600E mutation was also associated with organ involvement that could lead to permanent, irreversible damage, such as neurologic (75%) and pituitary (72.9%) injuries. Compared with patients with wild-type BRAF, patients with BRAF V600E more commonly displayed resistance to combined vinblastine and corticosteroid therapy (21.9% v 3.3%; P = .001), showed a higher reactivation rate (5-year reactivation rate, 42.8% v 28.1%; P = .006), and had more permanent, long-term consequences from disease or treatment (27.9% v 12.6%; P = .001). Conclusion: In children with LCH, BRAF V600E mutation was associated with high-risk features, permanent injury, and poor short-term response to chemotherapy. Further population-based studies should be undertaken to confirm our observations and to assess the impact of BRAF inhibitors for this subgroup of patients who may benefit from targeted therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2015.65.9508

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 22 references

Cited by

See all 342

Metadata

Authors
Héritier, S., Emile, J.-F., Barkaoui, M.-A., Thomas, C., Fraitag, S., Boudjemaa, S., Renaud, F., Moreau, A., Peuchmaur, M., Chassagne-Clément, C., Dijoud, F., Rigau, V., Moshous, D., Lambilliotte, A., Mazingue, F., Kebaili, K., Miron, J., Jeziorski, E., Plat, G., Aladjidi, N., Ferster, A., Pacquement, H., Galambrun, C., Brugières, L., Leverger, G., Mansuy, L., Paillard, C., Deville, A., Armari-Alla, C., Lutun, A., Gillibert-Yvert, M., Stephan, J.-L., Cohen-Aubart, F., Haroche, J., Pellier, I., Millot, F., Lescoeur, B., Gandemer, V., Bodemer, C., Lacave, R., Hélias-Rodzewicz, Z., Taly, V., Geissmann, F., & Donadieu, J.
Venue
Journal of Clinical Oncology
Published
2016-09-01
Volume
34
Issue
25
Pages
3023-3030
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2474782031
Cited by
342
References
22
FWCI
18.02
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy. https://app.cochat.ai/papers/10.1200/jco.2015.65.9508
The paper
Héritier, S., Emile, J.-F., Barkaoui, M.-A., Thomas, C., Fraitag, S., Boudjemaa, S., Renaud, F., Moreau, A., Peuchmaur, M., Chassagne-Clément, C., Dijoud, F., Rigau, V., Moshous, D., Lambilliotte, A., Mazingue, F., Kebaili, K., Miron, J., Jeziorski, E., Plat, G., . . . Donadieu, J. (2016). BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2015.65.9508

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.